Viatris reports fourth-quarter and full-year 2023 financial results and provides 2024 financial guidance

Pittsburgh , feb. 28, 2024 /prnewswire/ -- meets 2023 guidance for total revenues, adjusted ebitda and free cash flow[1]   reports 2023 total revenues of $15.4 billion, u.s. gaap net earnings of $54.7 million, adjusted ebitda of $5.1 billion, u.s. gaap net cash provided by operating activities of $2.8 billion and free cash flow of $2.4 billion    reports third consecutive quarter of operational revenue growth on a divestiture-adjusted basis in 2023 and expects to see continued growth in 2024[2]   immediately adds two phase 3 assets, selatogrel and cenerimod, both with blockbuster revenue potential, through global research and development collaboration with idorsia; announces r&d event to be held march 27, 2024    completes $250 million in share repurchases to date in 2024; board of directors increases share repurchase authorization by additional $1 billion, bringing total authorization to $2 billion    board of directors maintains dividend policy for 2024 of 48 cents ($0.48) per share and declares first quarter dividend of 12 cents ($0.12) per share viatris inc. (nasdaq: vtrs) today announced its financial results for the fourth quarter and full year 2023. financial impact of transactions and acquired ipr&d ($m) 2023 guidance ranges (november 7, 2023) – divestitures and acquisitions ( 1) – acquired ipr&d( 2) = 2023 adjusted guidance ranges 2023 results total revenues $15,400 - $15,600 ($35) — $15,365 - $15,565 $15,427 adjusted ebitda $5,000 - $5,400 ($20) ($105) $4,875 - $5,275 $5,124 free cash flow $2,300 - $2,700 ($235) ($100) $1,965 - $2,365 $2,423   as previously disclosed, guidance ranges as provided on november 7, 2023, included the full-year expected performance for the planned divestitures and excluded any potential related costs such as taxes and transaction costs, any similar costs related to the eye care acquisitions, as well as any acquired ipr&d.
VTRS Ratings Summary
VTRS Quant Ranking